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ABSTRACT
Objective: To analyse enquiries made in the Drug
Information Database (DID) to develop a better under-
standing of athletes’ interests and concerns regarding the
prohibited status of available substances.
Setting: Retrospective analyses of anonymous enquiries
recorded in the DID in 2006 and 2007.
Participants: Athletes and supporting personnel.
Results: The DID recorded 223 717 enquiries with 200 of
the .6000 UK licensed pharmaceutical products receiv-
ing over 100 enquiries each. The majority (79.2%) of
these enquiries were in the pharmaceutical product
category, followed by recreational drugs (10.4%). A
variety of common medications were subject to enquiry,
with anti-inflammatory agents, decongestants and
bronchodilators being most common; a trend in keeping
with reported medication use by athletes. Of all enquiries,
42% were not found owing to misspelled words or
enquiries about unregulated substances. The proportion of
enquiries about substances not listed in the database is
relatively high and has increased over the 24 month
observation period.
Conclusion: The DID is a well-used information resource
with some 10 000 enquiries being made each month. Of
the c. 60% of successful enquiries, the major focus was
on pharmaceutical products. With some 73% of enquiries
being made by the athletes themselves, further investi-
gations are warranted to explore enquiry patterns in
relation to specific sports. Of the unsuccessful enquiries, a
large number were related to nutritional supplements,
which warrants further investigation. The DID database
appears to be a valid mirror of athletes’ chemically
assisted practices and may be successfully used to inform
health professionals as well as antidoping prevention
programmes.
The widespread use of chemically assisted perfor-
mance enhancements in sport is a growing
concern, with the emphasis on the need for harm
reduction policies and intervention, underpinned
by empirical evidence from clinical trials.1
Considerable advances have been, and continue
to be, made in the development and application of
the analytical sciences that underlie the detection
of prohibited performance-enhancing substances
(PES) both in and out of competition. In addition
to advances in chemical testing,2 the widespread
adoption of the World Anti-Doping Agency
(WADA) code and harmonisation of testing and
international standards have facilitated the recent
gains in ‘‘policing’’ drug use in sports to a large
degree.3 The International Olympic Committee
(IOC)-sanctioned empirical testing of biofluids
(urine and blood) is being extended by the
exploratory analyses of hair samples, which are
recognised in forensic testing and toxicology but
are not accepted as sole evidence for a doping
offence.4–8 Alternative approaches to reduce drug
use in sports include education and studies
designed to elucidate the reasons that underlie
decisions to partake in drug use.
Practices of chemically assisted performance
enhancements reach beyond using prohibited drugs
and methods. Recent studies show that a note-
worthy proportion of athletes take nutritional
supplements daily9–12 and the majority of users of
supplements in sports fail to take appropriate
supplements to achieve their desired health-main-
tenance or performance-related outcomes.13–15 This
mismatch between rationale underlying supple-
ment use and the outcomes of the chosen
supplements could form part of an educational
programme to eradicate misplaced supplement use
in sports. However, these literature reports may
also be useful in designing new trials and testing
programmes to evaluate the side effects of supple-
ments. In addition to supplements, athletes com-
peting at international sport events reported an
alarmingly high use of a number and combination
of nutritional supplements, over-the-counter
(OTC) and prescription-only medications,11 16–19 a
pattern that is mirrored in sub-elite athlete
populations.20 Among Belgian athletes, the
reported use of OTC medication has increased
from 19.8% to 24.7% in 3 years (2002–5), with the
proportion of users above 35% in certain sports
(such as corticosteroids in cycling).21
Whilst antidoping prevention programmes tar-
get high-performing athletes, the use of perfor-
mance-enhancing substances has spread beyond
elite sports22 and is reaching epidemic proportions.1
The complexities of ranges of prescription and
over-the-counter medicines, social drugs and sup-
plements, along with the broad range of products
which contain them, necessitate an ever-watchful
eye from athletes and coaching teams so that
inadvertent doping does not occur. According to
the strict liability principle of the WADA Code, the
ultimate responsibility rests with the athlete and it
is irrespective of intention. A clear, authoritative
and accessible resource is required for athletes and
their support team to discriminate between readily
available drugs with varying prohibition status.
The risk to athletes is twofold: in addition to the
scenario of inadvertently failing a doping test, several
prescription and OTC medicines have known side
effects that may hinder an athlete’s performance.
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This concern is exemplified by the well-known gastric irritation
caused by some non-steroidal anti-inflammatory drugs (NSAIDs).23
In a report by Berglund and Sundgot-Borgen,24 estimated use of
NSAIDs is some six to tenfold higher in Olympic athletes than in
the age-matched Swedish population. However, it is notable that,
despite many estimates of higher use in athletes, only one study has
compared NSAID use with that in age-matched controls.16 Given
the paucity of rigorous studies on NSAID use by athletes, clearly a
great deal of research is warranted to obtain a clear picture of
prescription and OTC medicines use by athletes. A recent review by
Alaranta et al17 draws upon numerous studies that relate higher
prescription drug use by athletes whilst noting the potential
detrimental side effects. These include antiasthmatic and anti-
allergic medicines, along with NSAIDs and oral antibacterials.
Owing to the enormous number and variety of supplements,
prescription and OTC medicines available, along with a lack of
clear information regarding doping, further research is required
for information on which studies should be undertaken in terms
of drug types in order to inform WADA testing and antidoping
prevention programmes. One approach to this conundrum is to
utilise the drug information databases to study patterns of
athlete enquiries, assuming that enquiries are true reflections of
interest and behaviour or behavioural intention. While enquiries
do not necessarily equate to uses, it is reasonable to assume that
athletes make enquiries about the prohibited status of the drugs
or substances they are taking or considering for medical or
performance-enhancing reasons.
In a similar fashion, studies of the trends, patterns and
psychology that underpin drug use in sport may be useful for
further consideration, investigation or policing both now and in
the future. This approach may also be extended to potentially
inform WADA guidelines by monitoring the number of users,
substances and degrees of use that are made of drug information
databases. Through the UK Sport website, a comprehensive
Drug Information Database (DID)25 is available as a guide
regarding the non-prohibited/prohibited status of UK licensed
pharmaceuticals and OTC medicinal products in competitive
sport. A number of resources are used to keep the database up to
date, in line with the current WADA prohibited list, including
the British National Formulary,26 Chemist and Druggist27 and
Monthly Index of Medical Specialties.28 The DID is designed for
support staff and athletes performing at or above a given
standard in their sport, and is regularly updated each month and
fully verified twice a year by professionally trained pharmacists
with expertise in elite sport.
Aims
This report presents the analyses of patterns of use of the DID
during 2006 and 2007, as a function of enquiries made in the
following categories: i) user profile, ii) sport type, iii) frequency
of enquiries per substance, iv) success rates in finding the
substance of interest, v) class of substance, and vi) enquiries
regarding substances outside the remit of the database (ie,
unlisted substances). The primary aim of this report is to make
the first step toward developing a detailed picture and a better
understanding of interests and concerns of those involved in
sport (athletes and their support networks) regarding the
prohibited status of commercially available medicines, supple-
ments and performance-enhancing substances.
METHODS
The underlying assumption of this study is that enquiries
registered via the DID reflect the use or potential use of the
queried substance, hence providing a valid picture of the most
popular drugs and substances. The database is searchable
anonymously but does provide a unique reference number for
users to keep a record.29 The search can be made by brand name
or individual ingredients. Demographic information collected
along with the enquiry is limited to role (table 1) and sport
(table 2), where users must select from the drop-down list in the
response window. Country of purchase is also recorded. The
system allows users to type partial information (a word
fragment) into the search box and offers a detailed list of the
searched word or fragment of the name to choose from. The
result shows the prohibited status of the drug both in
competition and out of competition, lists the main active
ingredient and is provided with a reference number and the time
and date when the enquiry was made (fig 1). As the research
utilised a data set recorded anonymously and there was no
contact with participants, it was exempt from ethical review.
The timeframe of this investigation encompasses 24 months
between 1 January 2006 and 31 December 2007. With the
exception of the Olympic Games, the 24 month period is
suitably long to capture major sport events, including the lead-
up time to, and preparation for, the event. Data from the DID
database were downloaded and transferred into Excel work-
sheets, where ‘‘found’’ and ‘‘not found’’ (ie, unlisted substances)
data were kept separately. The smallest time-unit selected for
Table 1 Pattern of enquiries expressed as a function of enquirer
Enquiry made by
Number of enquiries (% of the total enquiries
made)
Athlete 136519 (73.1)
Parent 12620 (5.6)
Governing body official 9615 (4.3)
Coach 9907 (4.4)
Other 8599 (3.8)
General practitioner 8061 (3.6)
Student 6258 (2.8)
Pharmacist 4081 (1.8)
Teacher 1056 (0.5)
Table 2 Pattern of enquiries expressed by type of sport
Sport Number of enquiries (% of the total enquiries made)
Athletics 24137 (10.79)
All sports 20356 (9.10)
Rugby Union 16254 (7.27)
Swimming 15772 (7.05)
Cycling 9693 (4.33)
Ice hockey 7743 (3.46)
Football (FA) 7558 (3.38)
Cricket 5808 (2.60)
Gymnastics 5632 (2.52)
Rugby League 5338 (2.39)
Equestrian 4998 (2.23)
American football 4798 (2.14)
Shooting 4755 (2.13)
Rowing 4418 (1.97)
Basketball 4028 (1.80)
Hockey 3703 (1.66)
Archery 3654 (1.63)
Volleyball 3653 (1.63)
Canoeing 3428 (1.53)
Judo 2972 (1.33)
Total of the above sports 158 698 (70.94)
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this study was 1 month, but the DID system allows analyses
for each day of any given period. Substances in the ‘‘found’’
database were categorised by their main effect and whether
they were pharmaceutical drugs, nutritional supplements,
recreational drugs, herbal products or other. Unlisted substances
were categorised by their effect and checked against the WADA
Prohibited List 2006 and 2007.30 31 Statistical analyses were
conducted using Excel XP version and SPSS version 15.0.
RESULTS AND DISCUSSION
A total of 223 717 enquiries were made to the UK DID between
1 January 2006 and 31 December 2007. The number of enquiries
made each month varies considerably from 6558 to 12 480, with
a monthly average of 9322 (SD 1483). Ignoring the sequence,
the distribution of the monthly enquiries followed the normal
distribution curve (Kolmogorov–Smirnov Z = 0.503, p = 0.962,
where H0: normality assumed).
During the 24 month period of this investigation, enquiries
were made predominantly by athletes (73.1%), with parents,
governing body officials, teachers and coaches accounting for a
total of 14.8% of enquiries. Healthcare professionals (GPs and
pharmacists) and students made 5.4% and 2.8 % of the
enquiries, respectively (table 1).
In contrast to the heterogeneous pattern observed when
classified by enquirer, the pattern observed for type of sport
gives a much more even spread (table 2). Enquirers classified
themselves as track and field athletes in 10.79% of cases, with
‘‘all sports’’, rugby union and swimming scoring 9.10%, 7.27%
and 7.05% respectively. After cycling, with 4.33% of enquiries,
eight sports fell into the range between 2% and 3.5%, showing a
good spread throughout sporting types. In all, 20 categories
accounted for some 70% of all enquiries, athletics being the only
sport with over 10%.
While the number of enquiries made each month remained
within 1 standard deviation of the mean, there were two low
and two high peaks over the 24 month period (fig 2). The
months in which the numbers of enquiries made were below 1
SD of the mean were the Decembers of 2006 and 2007. The two
noticeable peaks (both above mean +2 SD) occurred in October
2006 and July 2007.
The pattern of enquiries for the two peaks (October 2006 and
July 2007) and for the two low winter months (December 2006
and 2007) did not diverge considerably from the overall pattern,
except for October 2006. In this month, only 62% of the
enquiries were made by athletes, whereas pharmacists con-
tributed an increased proportion (12.7%) of the total enquiries
made during October 2006, a phenomenon which warrants
further investigation. During the other peak, athletes’ contribu-
tion to the number of enquiries in July 2007 was slightly higher
(82%) than the overall mean of 73.1%, but no decrease stood
out among the other groups.
Figure 1 Search results for a non-prohibited (Tylenol) and a prohibited (Nandrolone) substance from the DID database.
Figure 2 Trend in the number of enquiries made between January
2006 and December 2007 via the Drug Information Database (DID).
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Detailed analyses did not provide any specific explanation for
the two ‘‘low frequency’’ months, but they revealed interesting
reasons for the two peaks. Enquiries made by pharmacists in
October 2006 alone contributed 33.9% to the total number of
enquiries made over the 24 month period. The remaining 66.1%
were comparatively evenly distributed between the remaining
23 months, with a mean of 2.9 (1.1)% (min = 1.2%,
max = 5.6%). As the numbers of enquiries made by other user
groups remained close to the monthly average, it can be
concluded that the noticeable increase in October 2006 was
owing to the elevated number of enquiries made by pharma-
cists. In contrast to the monthly average of 170 enquiries (130 if
October 2006 is excluded), pharmacists registered 1094 enquiries
in October 2006. Fifty-eight percent of the drugs in which
pharmacists showed an interest were found in the DID database,
with no specific pattern of substances in either data set.
The analysis of the other ‘‘peak’’, July 2007, provided a very
peculiar picture. The increased number of enquiries (8088)
during this month was owing to one particular type of sport:
‘‘equestrian’’ (including paralympic equestrian). There was over
a 50-fold increase in the number of enquiries from those who
registered as ‘‘equestrian’’ (3159 vs 61, excluding July 2007 from
the mean). July 2007 alone contributed 69% of all enquiries
from the equestrian sport in the observed 24 month period,
which warrants further exploration. The number of enquiries
made during each of the remaining 23 months did not diverge
considerably from the mean and remained under 100 per
month. Almost all of the total 3159 enquiries were registered as
made by athletes (3143; 99.5%). A similar pattern was found
among enquiries made by paralympic equestrian athletes. Of
the total 609 enquiries over the 24 month period, 516 enquiries
(85%) were registered at the DID website in July 2007, all
exclusively from athletes. Apart from the preceding month with
35 enquiries (5.7%), 28 from athletes, the number of enquiries
made was (10 in each month. Slightly over half (1696) of the
drugs equestrian athletes were interested in were found in the
DID, but without a particular pattern. The highest hit on the
licensed list was with 10 logged enquiries about sodium
bicarbonate, followed by mannitol (eight) and glycerol trinitrate
(six). Among the unlisted substances, dextrose was on the top
of the list with 15 enquiries, followed by cromoglycate (eight)
and sodium (seven).
Analyses of all the compounds for which enquiries were made
at the DID site demonstrated that an exponential curve exists,
with some 200 substances receiving more than 100 enquiries
each (fig 3). The horizontal line in fig 3 represents the cut off
point after the first 200 substances, ordered in decreasing order
of frequency. In order to make the exponential curve more
readable, normalising power transformation with e(20.5x) expo-
nent was used. Clearly, with enquiries for over 6000 substances,
there were a large number receiving a low number of enquiries.
The top 200 substances for which the highest numbers of
enquiries were received were categorised as i) pharmaceutical
products, ii) recreational drugs, iii) supplements or iv) herbal
products. These 200 substances constitute 20.3% of all enquiries
made, and each received between approximately 1700 and 100
enquiries. The majority (79.2%) of the enquiries made were in
the pharmaceutical product category, followed by recreational
drugs (10.4%), herbal products (4.2%) and nutritional supple-
ments (1.8%), whereas 4.3% of the first 200 substances were
categorised as ‘‘other’’ and were typically excipients in a
formulation. In the pharmaceutical product category, the
highest number of enquiries was made regarding substances
that are included in common medications, such as NSAIDs,
decongestants and bronchodilators (table 3).
Specifically, the most frequent enquiries were on variants of
salbutamol (1882), caffeine (1702) and ingredients of pain/fever
relievers (ibuprofen and paracetamol, 1412 and 1349, respec-
tively) and cold medications (ephedrine, 1151). Both ephedrine
and salbutamol are bronchodilators and their in-competition
use is prohibited. However, salbutamol may be used under the
therapeutic use exemption (TUE) scheme. For the pattern of
reporting expressed by active agents and other medications see
table 4. The high frequency of enquiries about NSAIDs and
bronchodilators is in keeping with the literature precedents.17
One possible explanation for the relatively high prevalence of
decongestants and asthma medications among the enquiries is
the exercise-induced asthma that has been documented among
winter endurance athletes.32 33 It is equally possible that these
substances have performance-enhancing effects but are allowed
if prescribed with evidence of medical need under the TUE
scheme. Therefore, further investigation is warranted into
sport-specific enquiries about potentially performance-enhan-
cing substances (ie, salbutamol, corticosteroids, etc).
The diversity of substances is reflected in the high number of
enquiries that were unsuccessful (ie, substances that were ‘‘not
found’’) which was 42%. The ratio of ‘‘found’’ to ‘‘not found’’
substances, which was calculated by dividing the number of
substances found by the number of enquiries unlisted in the
Figure 3 Number of enquiries per substance with frequency (y axis)
and substance type (x axis).
Table 3 Pattern of reporting expressed by class of active agent
Substance type Group
Frequency count (% of
the top 200 enquiries)
Local constituent NSAID 5929 (13.06)
Local constituent Corticosteroid 5051 (11.13)
Brand Multiple 4019 (8.86)
Brand Decongestant 3511 (7.74)
Brand Bronchodilator 3035 (6.69)
Local constituent Stimulant 2842 (6.26)
Local constituent Antihistamine 2554 (5.63)
Local constituent Stimulant (bronchodilator) 1474 (3.25)
Local constituent Antibiotic 1196 (2.64)
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DID, has been progressively decreasing since January 2006
(fig 4). The reasons for the presence of ‘‘not found’’ substances
are twofold: i) misspelled words are not recognised by the
system and are treated as a separate (not found) entry and ii)
enquiries made with regard to nutritional supplements, herbs
and other non-vitamin non-mineral substances are not under
the remit of the British National Formulary, Chemist and
Druggist and Monthly Index of Medical Specialties,26–28 and are
hence not included in the database.
In the 2 year period of investigation, 93 926 enquiries were
not found in the database. From the list of substances unlisted
in the DID, the 24 substances with a minimum of 100 enquiries
were categorised (table 5). This level of frequency is consistent
with the ‘‘found’’ data (fig 4). The most frequent ‘‘unlisted’’
enquiry was creatine (24.05%), followed by various commercial
products for muscle building (HMB, Maximuscle,
Methoxyisoflavone) and some form of sugar (dextrose, gluco-
samine) at 9.20% and 7.88% respectively.
Substances enquired about but not found in the DID contain
a mix of prohibited and non-regulated substances, with some
clearly prohibited compounds (steroids, b-blockers and canna-
bis). The list also contains stimulants used in commercially
available drinks (ie, taurine in Red Bull), and some natural
products may be capable of causing positive doping results (ie,
Tribulus terrestris). Commercial products for muscle building
are also prone to deliberate contamination (spiking) with
prohibited substances.34
CONCLUSIONS
In a survey among UK athletes, respondents believed that
unintentional doping offences are mainly caused by inadequate
labelling, changes in composition of supplements and lack of
information, and felt that increased awareness of the UK Sport
website and regularly updated list of acceptable supplements
would help to prevent inadvertent doping.35
Table 4 Pattern of reporting expressed by active agent
Substance
In-competition
Status
Out of competition
Status
Number of
enquiries
% of the first
200 enquiries
(45 381)
% of all
enquiries
(223 717)
Salbutamol Prohibited Prohibited 1882 4.2 0.84
Caffeine Not prohibited Not prohibited 1702 3.7 0.76
Ibuprofen Not prohibited Not prohibited 1412 3.1 0.64
Paracetamol Not prohibited Not prohibited 1349 3.0 0.60
Ephedrine Prohibited Not prohibited 1151 2.5 0.50
Cetirizine hydrochloride Not prohibited Not prohibited 767 1.7 0.34
Loratadine Not prohibited Not prohibited 709 1.6 0.32
Prednisolone Prohibited Not prohibited 697 1.5 0.31
Cocaine Prohibited Not prohibited 691 1.5 0.31
Pseudoephedrine
hydrochloride
Not prohibited Not prohibited 689 1.5 0.31
Cannabis Prohibited Not prohibited 671 1.5 0.29
Pseudoephedrine Not prohibited Not prohibited 650 1.4 0.29
Phenylephrine
hydrochloride
Not prohibited Not prohibited 617 1.4 0.27
Amoxicillin Not prohibited Not prohibited 550 1.2 0.25
Figure 4 Trend in the ratio of found to not-found substances over 2 years (2006–7).
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The DID is highly used, with a healthy spread of users from a
variety of sports, with some 75% of enquiries being made by the
athletes themselves. It is important to note that the DID only
covers the drugs that are sufficiently and robustly legislated to
minimise the risk of contamination (e.g. medicines). Therefore
supplements, herbal remedies and other non-herb non-mineral
substances are not covered in the DID. A variety of common
medications were enquired about, with anti-inflammatory
agents, decongestants and bronchodilators being most common.
As this finding is congruent with the self-reported use of OTC
and prescription medicines, this finding supports the assump-
tion that the DID data can be successfully used to learn about
the key ingredients of athletes’ medication and supplementa-
tion practices.
As there is growing concern about the use and potential
misuse of OTC medication among athletes, developing a better
understanding of drug use by athletes is crucially important for
policy makers and health professionals alike for testing and
advisory functions. The literature typically focuses on a single
(major) sport event, and can therefore only give a snapshot of
athletes’ medication; this investigation adds useful information
accumulated over 2 years. Results from this paper can also offer
a unique contribution to the UK antidoping prevention
programmes by providing information otherwise unavailable.
The anonymity of the DID, coupled with the importance of
providing correct information (ie, drug name, constituents, or
sports), is likely to yield reliable information. Future research
will aim to i) expand the timeframe of the investigation with
specific attention to the months leading up to the multi-sport
events (Olympic Games, Commonwealth Games, etc.), ii)
expand the investigation to all substances enquired, iii)
investigate OTC and prescribed medication use by sports and
iv) research substances not found in the current DID.
Furthermore, the results of this paper highlight the need for
an improved feedback mechanism when the substance is
non-recognised. Improvement can include information on
assessing the risk of supplements, warning about potential
contamination (especially if the substance is purchased from an
unregulated source) and a link to the UK Sport position
statement regarding supplements.
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successfully used to inform antidoping prevention
programmes.
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